Annual Reports

Highlights

Second 12 month exclusive evaluation agreement signed with a major consumer healthcare company.
Continued collaboration with Procter & Gamble under joint development agreement.
Positive clinical results for lead dermatological compound in Phase II cosmetic study of acneic skin.
Turnover increased by 34.8% to £190,000 (2008: £141,000) following further commercial agreements entered into during the year with operating losses reduced by 17.5% to £1.29m.
Planned equity issue during the current financial year in order to fully progress commercial opportunities.

Highlights

Positive results from Phase II cosmetic study which show significant promise as a new cosmetic treatment for acne.
First commercial exclusive evaluation agreement in oral healthcare signed with major consumer healthcare company.
Joint development agreement, to investigate uses for Syntopix’s novel antimicrobial technology, signed with Procter and Gamble, the world’s largest consumer goods product company.
Revenue increased to £141,000 (2007: £31,000).
Further £1.5 million of funding raised in August 2008 through a placing of new shares to support further clinical studies.

Highlights

Phase I study completed in August 2007, validating the group’s methodology for determining the potential of compounds as acne treatments.
Phase II cosmetic study began in June 2007 and will report later this year.
An in vivo study is planned to begin shortly to study the effectiveness of our compounds against the staphylococcus aureus bacterium.
More than 300 compounds from our library have now been shown to exhibit significant antimicrobial activity.
Board of directors and scientific advisory panel strengthened with key appointments.
Careful control of expenditure resulting in cash balances at 31 July 2007 of £1.5 million (2006: £3.2 million).
Significant news flow anticipated during the next twelve months.

Highlights

Successful flotation on AIM in March 2006 via a placing raising £4 million gross.
Significant progress in delivery of Group's strategy using reduced risk and reduced cost business model.
Three lead candidates selected for pre-clinical and formulation studies.
Board and Scientific Advisory Panel strengthened.

Syntopix